Activation or mutation of cellular proto-oncogenes may be important events in tumor initiation, promotion and/or progression. The main goals of the studies presented in this proposal are to assess the expression of oncogene products, in particular, c-ras and c-myc in fresh tissue from human colon polyps, primary colon tumors and in metastatic lesions of these tumors, to determine if abnormal expression of these proto-oncogenes correlates with any of the stages of tumor development. The expression of activated c-ras proto-oncogenes (as determined by transfection assays) has been implicated in a variety of tumors. The proto-oncogenes of the myc family are amplified in many malignancies, sometimes at specific stages and indicative of prognosis. In some tumor cells, both a c-myc and c-ras proto-oncogene are aberrantly expressed. With the availability of fresh human tumor tissues at M.D. Anderson Hospital and Tumor Institute, the hypothesis that aberrant expression of one or both of these oncogenes correlates with some of the stages of colon malignancies will be tested. Colon tumors are a particularly good system for these studies because of familial polyposis coli (FPC) syndromes, in which slow development from polyp to carcinoma is inevitable barring surgical intervention. Thus, we will analyze as many types of polyps as can be obtained, including polyps from FPC patients, and malignant colorectal carcinomas of each of the Dukes' stages (in situ, B1, B2, C, D, and metastases to different organs). This study focuses on the protein products of these oncogenes, including determining the prevalence of mutated c-ras proteins, and immunoperoxidase studies onfixed tissue specimens to examine individual cells within the tumor, comparing them to adjacent normal tissues. The latter studies will be performed in collaboration with a member of the Pathology Department of this Institution. Thus, this study will represent the first to comprehensively assess the proto-oncogene products in fresh hauman tissue. Also included in this study are collaborating efforts with members of the Institution on the cytogenetics of the tumor cells as well as expression of mRNA and oncogene structure. The data obtained should be useful in understanding the mechanism(s) by which aberrant expression of c-ras genes may participate in tumorigenesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Unknown (R23)
Project #
5R23CA039803-03
Application #
3446725
Study Section
Chemical Pathology Study Section (CPA)
Project Start
1985-12-01
Project End
1989-06-30
Budget Start
1987-12-01
Budget End
1989-06-30
Support Year
3
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Hospitals
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Nicolson, G L; Gallick, G E; Spohn, W H et al. (1992) Transfection of activated c-H-rasEJ/pSV2neo or pSV2neo genes into rat mammary cells: rapid stimulation of clonal diversification of spontaneous metastatic and cell-surface properties. Oncogene 7:1127-35
Nicolson, G L; Gallick, G E; Dulski, K M et al. (1990) Lack of correlation between intercellular junctional communication, p21rasEJ expression, and spontaneous metastatic properties of rat mammary cells after transfection with c-H-rasEJ or neo genes. Oncogene 5:747-53
Donato, N J; Ince, C; Rosenblum, M G et al. (1989) Early events in the antiproliferative action of tumor necrosis factor are similar to the early events in epidermal growth factor growth stimulation. J Cell Biochem 41:139-57
Donato, N J; Gallick, G E; Steck, P A et al. (1989) Tumor necrosis factor modulates epidermal growth factor receptor phosphorylation and kinase activity in human tumor cells. Correlation with cytotoxicity. J Biol Chem 264:20474-81
Maxwell, S A; Sacks, P G; Gutterman, J U et al. (1989) Epidermal growth factor receptor protein-tyrosine kinase activity in human cell lines established from squamous carcinomas of the head and neck. Cancer Res 49:1130-7
Lai, C N; Gallick, G E; Maxwell, S A et al. (1988) Potassium inhibition of transforming protein P85gag-mos and reversal of the transformed phenotype in 6m2 cells. J Cell Physiol 134:445-52
Lichtner, R B; Gallick, G E; Nicolson, G L (1988) Pyrimido-pyrimidine modulation of EGF growth-promoting activity and p21ras expression in rat mammary adenocarcinoma cells. J Cell Physiol 137:285-92
Ro, J; North, S M; Gallick, G E et al. (1988) Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma. Cancer Res 48:161-4
Weber, R S; Pathak, S; Frankenthaler, R et al. (1988) Effect of epidermal growth factor (EGF) on a newly established head and neck squamous carcinoma cell line. Otolaryngol Head Neck Surg 99:567-73
Yoshida, M; Gallick, G E; Irimura, T et al. (1987) Modification of cell surface glycoproteins, macrophage cytostasis, and blood-borne metastatic properties of the murine RAW117 large cell lymphoma by virus superinfection. Cancer Res 47:2558-62

Showing the most recent 10 out of 14 publications